Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Sales (2020 - 2025)

Maxcyte (MXCT) has disclosed Return on Sales for 6 consecutive years, with 2.01% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 323.0% to 2.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.13% through Dec 2025, down 88.0% year-over-year, with the annual reading at 2.13% for FY2025, 107.0% down from the prior year.
  • Return on Sales for Q4 2025 was 2.01% at Maxcyte, up from 1.82% in the prior quarter.
  • The five-year high for Return on Sales was 2.01% in Q4 2025, with the low at 4.29% in Q4 2021.
  • Average Return on Sales over 5 years is 1.0%, with a median of 1.17% recorded in 2022.
  • The sharpest move saw Return on Sales plummeted -544bps in 2021, then surged 408bps in 2022.
  • Over 5 years, Return on Sales stood at 4.29% in 2021, then soared by 95bps to 0.21% in 2022, then skyrocketed by 517bps to 0.86% in 2023, then crashed by -241bps to 1.22% in 2024, then soared by 265bps to 2.01% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 2.01%, 1.82%, and 1.45% for Q4 2025, Q3 2025, and Q2 2025 respectively.